Clinical effect of amifostine combined with erythropoietin in the treatment of patients with MDS

ZHU Linyan; WANG Yufang; CHEN Shiming; KE Jinyong

doi:10.3969/j.issn.1671-6450.2014.11.012

Abstract：Objective To investigate the effect of amifostine combined with erythropoietin in the treatment of myelo -dysplastic syndrome ( MDS) .Methods Twenty-eight MDS patients from the Department of internal medicine were randomly divided into combined group and control group with 14 cases in each group , the control group used amifostine intravenous infu-sion of 0.5 g, the combined group besides the treatment as the control group , also use of erythropoietin 6 000 U subcutaneous injections, 3 times/week, the course of treatment was 3 months, the clinical curative effect of 2 groups were compared .Re-sults Before treatment, white blood cells, platelets, hemoglobin did not show significant difference between the 2 groups (P >0.05), after treatment, these indices in the 2 groups were increased but the difference was not statistically significant (P >0.05), after 3 months of treatment, blood transfusion and transfusion volume reduced more than 50%’s proportion in the combined group was 78.57%, higher than 35.72%in the control group, the difference was statistically significant (χ2 =5.250, P =0.022).The combined group’s total effective rate was 78.57%, higher than 64.29%in the control group, but the difference was not statistically significant (χ2 =0.700, P =0.403).The 1 year survival rate of 2 groups of patients were 100%, 2 year survival rate , compared with the 3 year survival rate , the combined group were higher than that of control group (78.57%vs.57.14%, 57.14%vs.35.71%), but the difference was not statistically significant ( P >0.05).Combined group’s median survival time was 32 months, significantly longer than the 25 months in the control group (χ2 =3.532, P =0.038).Conclusion Amifostine combined with erythropoietin in the treatment of MDS have certain effect to improve the blood and the survival time of the patients .